NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC decreased its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 1.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 822,300 shares of the company’s stock after selling 15,068 shares during the quarter. TimesSquare Capital Management LLC’s holdings in NewAmsterdam Pharma were worth $28,846,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Farther Finance Advisors LLC raised its stake in NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after acquiring an additional 708 shares during the period. Navalign LLC acquired a new stake in NewAmsterdam Pharma during the fourth quarter worth about $46,000. Wolverine Asset Management LLC acquired a new stake in NewAmsterdam Pharma during the third quarter worth about $69,000. NBC Securities Inc. acquired a new stake in NewAmsterdam Pharma during the fourth quarter worth about $86,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in NewAmsterdam Pharma by 26.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,510 shares of the company’s stock worth $193,000 after acquiring an additional 1,156 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Trading Down 3.7%

Shares of NASDAQ:NAMS opened at $34.14 on Tuesday. The firm’s 50 day moving average is $32.41 and its two-hundred day moving average is $34.30. NewAmsterdam Pharma Company N.V. has a 52 week low of $16.78 and a 52 week high of $42.21. The firm has a market capitalization of $3.99 billion, a P/E ratio of -19.07 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The firm had revenue of $3.04 million during the quarter. Analysts predict that NewAmsterdam Pharma Company N.V. will post -1.76 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on NAMS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. Needham & Company LLC increased their price objective on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Royal Bank Of Canada raised their price target on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $48.00.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CEO Michael H. Davidson sold 443,707 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $33.25, for a total value of $14,753,257.75. Following the sale, the chief executive officer owned 174,144 shares in the company, valued at approximately $5,790,288. This trade represents a 71.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Louis G. Lange sold 44,619 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $30.42, for a total transaction of $1,357,309.98. Following the completion of the sale, the director owned 10,360 shares in the company, valued at $315,151.20. The trade was a 81.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 1,168,286 shares of company stock worth $38,211,967. 12.74% of the stock is owned by company insiders.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.